Nishina, Tomohiro
Azuma, Mizutomo
Nishikawa, Kazuhiro
Gotoh, Masahiro
Bando, Hideaki
Sugimoto, Naotoshi
Amagai, Kenji
Chin, Keisho
Niwa, Yasumasa
Tsuji, Akihito
Imamura, Hiroshi
Tsuda, Masahiro
Yasui, Hirofumi
Fujii, Hirofumi
Yamaguchi, Kensei
Yasui, Hisateru
Hironaka, Shuichi
Shimada, Ken
Miwa, Hiroto
Mitome, Terukazu
Kageyama, Hiroki
Hyodo, Ichinosuke
Article History
Received: 30 March 2018
Accepted: 1 June 2018
First Online: 9 June 2018
Compliance with ethical standards
:
: Tomohiro Nishina has received honoraria from Yakult Honsha and Taiho Pharmaceutical. Kazuhiro Nishikawa has received grants and personal fees from Yakult Honsha, personal fees from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly and EA Pharma. Masahiro Gotoh has received grants, personal fees and non-financial support from Taiho Pharmaceutical, non-financial support from Yakult Honsha, personal fees and non-financial support from Bristol-Myers Squibb, Chugai Pharmaceutical, Takeda Pharmaceutical, Kyowa Hakko Kirin, Novartis Pharmaceutical, Sumitomo Dainippon Pharma, Bayer and Ono Pharmaceutical. Hideaki Bando has received research funds from Astra-Zeneca and Chugai Pharmaceutical, honoraria from Taiho Pharmaceutical and Eli Lilly. Naotoshi Sugimoto has received honoraria from Yakult Honsha, Taiho Pharmaceutical, Eli Lilly, Merck Serono and Chugai Pharmaceutical. Kenji Amagai has received research funding from Taiho Pharmaceutical and MSD. Akihito Tsuji has received honoraria from Yakult Honsha and Taiho Pharmaceutical. Kensei Yamaguchi has received personal fees from Taiho Pharmaceutical, Bayer, Bristol-Myers Squibb, Merck Serono, Chugai Pharmaceutical and Takeda Pharmaceutical. Hisateru Yasui has received personal fees from Medicon. Hisateru Yasui has received honoraria from Yakult Honsha, Taiho Pharmaceutical, Chugai Pharmaceutical, and Medicon Inc. Shuichi Hironaka has received honoraria from Yakult Honsha, Taiho Pharmaceutical, and Novartis Pharmaceutical. Ken Shimada has received honoraria from Yakult Honsha, Taiho Pharmaceutical, Chugai Pharmaceutical and Kyowa Hakko Kirin. Terukazu Mitome and Hiroki Kageyama are employees of Yakult Honsha, which produced oxaliplatin used in the G-SOX study from which data were obtained for the present analysis. Ichinosuke Hyodo has received advisory fees and honoraria from Yakult Honsha, Taiho Pharmaceutical and Chugai Pharmaceutical. The other authors have declared no conflicts of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or a substitute for it was obtained from all patients for being included in the study.